Crime-fighting 'Tebow' the dog catches drug smuggler USA TODAY By Michael McCarthy, USA TODAY Tebowmania continued over the weekend even though Tim Tebow and the Denver Broncos lost to Tom Brady and the New England Patriots. A drug-sniffing dog named "Tebow" help cops catch a cocaine smuggler at Orlando … Defensive switch key to Patriots' victoryBoston Herald
Broncos' Fox assesses the lossBoston.com Dan Shaughnessy Tim Tebow runs out of miracles vs. PatriotsThe Boston Globe CBS News -SB Nation -al.com all 1,749 news articles »
Ex-'Thor 2' Director Brian Kirk To Helm Guillermo Del Toro Produced Drug Drama … Indie Wire (blog) Last month, TV helmer Brian Kirk was passed up for “Thor 2” directing duties in favor of “Monster” director, Patty Jenkins. Now, Kirk is moving on to less-CGI filled pastures, signing on to direct “Midnight Delivery,” a film about a father who must … 'Game of Thrones' Director Brian Kirk to Helm Guillermo del Toro-Produced …/FILM (blog)
Brian Kirk to Direct Guillermo del Toro-Produced Thriller MIDNIGHT DELIVERYMovies.ie Brian Kirk Signs To Direct del Toro ThrillerThe Irish Film Television Network IGN -Collider.com -Variety all 12 news articles »
Glaxo, Human Genome Win Approval for 1st Lupus Drug in Years
GlaxoSmithKline Plc (GSK) and Human Genome Sciences Inc. (HGSI) won U.S. approval to sell Benlysta, a potential $3.6 billion product that will be the first new drug in 52 years for the auto-immune disease lupus.
Medical experts say first new lupus drug since 1950s could spur more research on disease
WASHINGTON – The U.S. Food and Drug Administration has approved the first new drug to treat lupus since 1955, a milestone that medical experts say could prompt development of other drugs that are even more effective in treating the debilitating illness.
www.StockMarketFunding.com (HGSI) Human Genome Sciences Benlysta Drug Approval for Lupus Patients. New Break through in Human Genome Sciences Benlysta drug approval for lupus patients. Will the Benlysta FDA Approval Come? We believe so at SMF and we will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in “biotechnology” in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies — antibodies that attack and destroy the body’s own healthy tissues. BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a …
Louisville biotech firm’s drug could improve a broodmare’s chance of pregnancy on the first date
At Valentine’s Day, the Thoroughbred industry’s thoughts turn to the breeding shed, where
Biotech Stocks: Mannkind pressures drug stocks
Shares of Mannkind Corp. sank 20% on news that it was laying off 41% of its workforce in order to focus its resources on its troubled inhaled insulin product Afrezza.
Amgen to buy experimental cancer drug maker Biovex in $1bn deal
Amgen, the world’s largest biotechnology company, said it agreed to buy Biovex, a closely-held maker of experimental cancer drugs for $425m plus as much as $575m in milestone payments.
PolyMedix Promotes Bozena Korczak to Senior Vice President, Drug Development and Chief Development Officer
PolyMedix, Inc. , an emerging biotechnology company focused on developing new therapeutic drugs for the treatment of serious infectious diseases and acute cardiovascular disorders, announces the promotion of Bozena Korczak, Ph.D. to Senior Vice President, Drug Development and Chief Development Officer.
Bay Biz Buzz: Xoma to develop diabetes drug with French firm
Berkeley-based Xoma Ltd., an unprofitable 30-year- old biotechnology company, will get an initial payment of $35 million and may earn as much as $800 million more from Les Laboratoires Servier to share development of a medicine for diabetes and other disorders.
